New drug HS-10518 put to the test in healthy volunteers
NCT ID NCT07264192
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and tolerability of a new drug called HS-10518 in 60 healthy premenopausal women in China. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. The goal was not to treat any disease, but to gather essential safety data before future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFERTILITY, FEMALE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Second University Hospital
Chengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- IVF Needle-Free? oral pill tested as injection alternative
- Obesity may blunt the Brain's ovulation signal, study hints
- Could a fibroid drug help women with adenomyosis finally achieve a live birth?
- Could a blood injection revive aging ovaries?
- Could a shot of your own blood help your ovaries produce more eggs?
- Blood plasma injection aims to wake up dormant ovaries in menopause